SAGE - Sage cuts 40% of staff in portfolio shake-up ahead of Zurzuvae launch
2023-08-31 07:22:43 ET
More on Sage
- Sage Therapeutics: Undeserving Selloff Presents A Buying Opportunity
- Sage Therapeutics, Inc. ( SAGE ) Business Update Call (Transcript)
- Sage Therapeutics' Zuranolone Is A Lost Cause In Depression Market
- Sage Therapeutics: Zuranolone August Approval Likely, Opportunity Uncertain
- Biogen/ Sage expected to hike price for new depression drug after narrow label
- RBC Capital cuts Sage to sector perform, calls FDA decision "major setback"
- Wedbush cuts Sage to neutral, questions Biogen's future funding of zuranolone
For further details see:
Sage cuts 40% of staff in portfolio shake-up ahead of Zurzuvae launch